Stay updated on Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial
Sign up to get notified when there's something new on the Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial page.

Latest updates to the Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision label updated to v3.3.4; the previous v3.3.3 label has been removed.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedLocations for Ontario and Saskatchewan were added and the HHS Vulnerability Disclosure link removed; page revision updated to v3.3.3.SummaryDifference0.3%

- Check58 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; this appears to be a backend version update with no impact on study content, eligibility criteria, outcomes, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedThe funding-status notice warning about potential delays and updates due to funding lapses was removed from the page.SummaryDifference0.4%

- Check79 days agoChange DetectedStudy status updated to Terminated with enrollment closed due to slow accrual; primary outcome analysis was not performed.SummaryDifference0.5%

- Check108 days agoChange DetectedAdded a government-status notice and updated version to v3.2.0; removed the old v3.1.0 tag. The page now communicates current operating status and a new version release.SummaryDifference4%

Stay in the know with updates to Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial page.